Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05669105

Enrollment

200

Registered

2022-12-30

Start date

2022-02-19

Completion date

2024-03-31

Last updated

2023-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung Cancer

Keywords

lung cancer, NSCLC

Brief summary

The study objective is to collect biospecimen samples (e.g., whole blood) from participants diagnosed with active lung cancer to investigate the immune response to develop treatments and therapies.

Interventions

DIAGNOSTIC_TESTSpecimen sample

Participants will have up to 100 mL of whole blood collected.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* Participants willing and able to provide written informed consent * Participants are willing and able to provide appropriate photo identification * Participant's age 18 - 100 years old * Participants diagnosed with active non-small cell lung cancer (Adenocarcinoma or Squamous Cell only. All stages are acceptable.) * Participants must have associated tissue biomarker data (EFGR and MET mutations) in their medical records

Exclusion criteria

* Participants who are pregnant or nursing * Participants with a known history of HIV, hepatitis, or other infectious diseases * Participants who have taken an investigational product in the last 30 days * Participants who have experienced excess blood loss, including blood donation defined as 250 mL in the last month or 500 mL in the previous two months * Participants currently enrolled in a clinical trial * Participants currently in remission

Design outcomes

Primary

Measure	Time frame	Description
Biospecimen & Clinical Data Collection	10 years	The primary objective is to collect 2000 whole blood samples from subjects who are diagnosed with active lung cancer. The purpose of this study is to collect biospecimen samples (e.g., whole blood) from participants diagnosed with various active lung cancers so that investigations can analyze how the immune response can take place, and aid in understanding active lung cancer biomarkers for future early diagnosis and treatment options.

Countries

United States

Contacts

Primary ContactThomas Goslin

tgoslin@sanguinebio.com(818) 583-8844

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026